Category - MRK

AGN AKCA ALNY ALXN AMGN AMRN ARGX ARNA ARRY ATRA AZN BCRX BIIB BMY CDXS CELG CFA CORT CVS DCPH DNLI ELY ESPR ESRX EXEL FATE Games GBT GSK GWPH HCM IBB ICPT INCY JNJ LABD LABU MRK MRNA MRTX NKTR NVO NVS PFE PRQR REGN SPY Tarun Chandra TSRO VCEL VNDA VRTX XBI XLV

Biotech Bonanza: 2019 Outlook On An Uphill Battle

Contents 1 Biotech Pulse 2 Regulatory Panorama To Stay Comparable However Noisier 3 Biotech Pipeline Stays Wealthy With Potential 4 Mergers & Acquisitions...

AGCO ANAT AVT AXP AZO BAX BIDU BK BRK.A BRK.B CKX CMCSA CNHI COP CSCO CTWS DEO DVN EMR Games GOOG GOOGL GSK HAL HSBC JNJ John Vincent KOF MA MMM MRC MRK NSRGY NVS NWLI PSX RDS.A RDS.B RHHVF SAFRF SAFRY SHEN TBCUX TBGVX TBHDX TMK TOT TWEBX UL UN UNF UNP USB VZ WFC WPP

Tracking Tweedy Browne Portfolio – Q3 2018 Update

This text is a part of a collection that gives an ongoing evaluation of the modifications made to Tweedy Browne’s 13F portfolio on a quarterly foundation...

ACAD AMGN AMRN ARRY ARWR CDNA CFA EBS ECYT ENDP EXAS FATE Games GILD GKOS IBB ICPT IMMU JNJ LLY MRK NBIX NVS PCRX PFE PRQR RARX RGNX SRPT Tarun Chandra VKTX VNDA XBI XLRN

A Migrating Biotech Bear | Seeking Alpha

Contents 1 Biotech Pulse 2 A Transitory Biotech Bear 3 Biotech Fundamentals Unchanged After Coverage Information 4 In October, there have been two main...

ACAD ADAP ALDR AMGN AMRN ARWR BMRN BMY CFA ECYT ELY ENDP FATE Games GILD HHS IBB IWM JNJ LOXO MRK NBIX NVS PFE PRQR QQQ RARX REGN RGNX SNF SPY SRPT Tarun Chandra VKTX VNDA VRTX XBI XLRN

Biotech Stocks Bloodied But Can Now Drive M&A

The precipitous, waterfall-like, decline in indexes this month was led by the sliding small-cap and biotech indexes. The chart under exhibits the anatomy of...

AAPL ADM AIV AIZ AMD AMGN AMP Andres Cardenal APA APC BHF BMY CBRE CELG CF CFA CHRW CINF CMI CSX CTAS DE DRI EOG ETFC ETN ETR Games GILD GRMN GWW HES HFC INCY KMX LNC MOS MPC MRK NFX NTAP OXY PAYX PFG PGR PXD REGN RJF SCHW SPY TROW UNP VLO XEC

Protect Your Portfolio And Increase Returns By Focusing On Earnings Trends

Simplicity is the last word sophistication. There’s an virtually infinite quantity of variables to think about when making funding selections...